Barker outlined why the Vitatene offer, which is subject to regulatory approval, fitted with DSM Nutritional Product’s ‘natural’ strategy, which also motivated the Martek Biosciences buy-out last year.
Going forward, “we are always looking at new acquisitions” Morgan stated. “We have a shortlist which will fit our strategic direction – we’re always looking for all opportunities within our arena. But who and when only time will tell.”